Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.
The new licensing deal between Akebia and Otsuka expands upon a pact made last December for U.S. commercial rights.
Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.
When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.